A Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric Patients With Spinal Muscular Atrophy Who Experienced a Plateau or Decline in Function After Gene Therapy

Recruiting

RisdiplamA Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric Patients With Spinal Muscular Atrophy Who Experienced a Plateau or Decline in Function After Gene Therapy

Sponsor:

Hoffmann-La Roche

Code:

NCT05861999

Conditions

Muscular Atrophy, Spinal

Eligibility Criteria

Sex: All

Age: 3 - 24

Healthy Volunteers: Not accepted

Interventions

risdiplam

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-08-25. This information was provided to ClinicalTrials.gov by Hoffmann-La Roche on 2025-05-13.